Our reporters bring you news and highlights from BIO’s in-person and virtual events.
The journey of the data point is no longer linear, as advanced digital innovations are now employed throughout all the phases of drug development, […]
The data point is no longer linear, say data scientists Read More »
Thanks to gene therapies, previously untreatable diseases are now treatable and patient quality of life has improved exponentially. Yet, gene therapy regulatory challenges, along
How gene therapy regulatory challenges impact R&D, manufacturing, patients Read More »
John Trizzino, Executive Vice President, Chief Commercial Officer, and Chief Business Officer of Novavax, joined Good Day BIO Live at the BIO International Convention,
Vaccine in 100 days ‘extraordinarily possible,’ says John Trizzino of Novavax Read More »
Misinformation. Not COVID. Not heart disease. Not cancer. Misinformation. That’s what the Commissioner of the U.S. Food and Drug Administration recently declared the leading
BIO Board Member: Biotech’s voice needs to get louder – and clearer Read More »
The FDA’s Accelerated Approval pathway has assisted America’s biotech industry in making remarkable advances over the last 30 years—but it has come under political
Accelerated Approval is under political attack, experts say Read More »
Over the last 25 years, licensing of academic patents from universities and nonprofits has made a major contribution to U.S. GDP, industrial gross production,
Licensing academic patents added $1 trillion to U.S. economy, says report Read More »
NASA astronaut Kjell Lindgren beamed in to the 2022 BIO International Convention – live from the International Space Station. He spoke to the more
NASA astronaut joins BIO International Convention – from space Read More »
On Day 4 – the final episode of Good Day BIO Live – we have interviews with BIO leadership and policy experts on Accelerated
Good Day BIO LIVE! from San Diego – watch Thursday’s episode Read More »
Accelerated Approval, growing misinformation and declining life expectancy, and the need for more resources on the food side of the agency were among the
FDA Commissioner on Accelerated Approval, misinformation, and food Read More »
The draft of the next Food and Drug Administration (FDA) user fee agreement currently making its way through Congress was developed with close cooperation
PDUFA panelists praise FDA’s cooperation on setting drug approval process Read More »
